Zafemy Patch
Product Images NDC 65162-358

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Zafemy (NDC 65162-358). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Where To Put Patch (Zafemy Norelgestromin And Ethinyl Estradiol Transd 1)

FDA Label Image

Figure 5 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 10)

FDA Label Image

Figure 6 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 11)

FDA Label Image

Flow Chart (Zafemy Norelgestromin And Ethinyl Estradiol Transd 12)

FDA Label Image

Calendar (Zafemy Norelgestromin And Ethinyl Estradiol Transd 13)

FDA Label Image

Patient Information Graph (Zafemy Norelgestromin And Ethinyl Estradiol Transd 14)

FDA Label Image

Figure A (Zafemy Norelgestromin And Ethinyl Estradiol Transd 15)

This appears to be a set of medical data related to pregnancy and blood clots. It contains information on the number of women with blood clots out of 10,000 woman-years based on various factors such as pregnancy status and postpartum period. It also includes the range of values for each of these factors.*

FDA Label Image

Figure B (Zafemy Norelgestromin And Ethinyl Estradiol Transd 16)

FDA Label Image

Where To Put Patch (Zafemy Norelgestromin And Ethinyl Estradiol Transd 17)

FDA Label Image

Usage Illustration 1 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 18)

FDA Label Image

Usage Illustration 2 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 19)

FDA Label Image

Usage Illustration 1 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 2)

FDA Label Image

Usage Illustration 3 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 20)

FDA Label Image

Usage Illustration 4 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 21)

FDA Label Image

Pouch (Zafemy Norelgestromin And Ethinyl Estradiol Transd 22)

FDA Label Image

Carton (Zafemy Norelgestromin And Ethinyl Estradiol Transd 23)

ZAFEMY™ is a transdermal system containing norelgestromin and ethinyl estradiol with a strength of 150/35 mcg per day. The product is contraindicated in pregnancy. The remaining text is not-readable.*

FDA Label Image

Zafemy Norelgestromin And Ethinyl Estradiol Transd 24

ZAFEMY is a transdermal system used to prevent pregnancy. It contains norelgestromin and ethinyl estradiol and is intended to be worn for 7 days as prescribed. The package contains 3 transdermal systems and must be stored at 20° to 25°C (68° to 77°F). ZAFEMY does not protect against HIV infections (AIDS) and other sexually transmitted diseases. The product is distributed by Amneal Pharmaceuticals LLG from Bridgewater, NJ 08807. The RX label must be placed on the package to use it.*

FDA Label Image

Usage Illustration 2 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 3)

FDA Label Image

Usage Illustration 3 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 4)

FDA Label Image

Usage Illustration 4 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 5)

FDA Label Image

Figure 2 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 6)

This appears to be a medical document with information on pregnancy and postpartum care. The text includes categories for non-pregnant women, pregnant women, and postpartum women, along with different ranges for certain factors such as weeks of pregnancy and blood clot incidents. The number 0 at the bottom may refer to the number of women with blood clots out of 10,000 woman-years.*

FDA Label Image

Structural Formula (Zafemy Norelgestromin And Ethinyl Estradiol Transd 7)

This text presents several studies that address the risk of breast cancer associated with the use of combined oral contraceptives. The studies were conducted between 2002 and 2017, and some of them analyze the risk of both ever-use and current-use. The table at the end of the text presents the effect estimates (OR/RR) obtained by the studies.*

FDA Label Image

Figure 3 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 8)

FDA Label Image

Figure 4 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.